GlassScriptPhysician profile
Howard Chang
NPI 1811632433
$5,484.26
in general payments reported to CMS, 2019-2025
19 companies · $2,875 in 2025
The $2,875 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $259 · 2024: $2,350 · 2025: $2,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,469 · Education: $15.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,469.22 |
| Education | $15.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.36 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $662.04 | 2023-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $559.42 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $462.64 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $446.35 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $430.06 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $404.18 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $369.99 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $292.21 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $272.62 | 2024-2025 | Rexulti |
| Corium, LLC | $271.72 | 2023-2025 | Azstarys |
| Indivior INC. | $201.29 | 2024-2025 | Sublocade, Perseris |
| Supernus Pharmaceuticals, INC. | $185.95 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $64.40 | 2024-2025 | Trintellix |
| Almatica Pharma LLC | $31.24 | 2025 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $20.19 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $17.87 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.69 | 2025 | Relexxii |
| Tonix Medicines, INC. | $14.04 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.